Evidence map›Paper›PMID 28004623›Full record

ArticleEpidemiology and psychiatric sciences2017

New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base.

G Ostuzzi, D Papola, C Gastaldon, C Barbui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epidemiology and psychiatric sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

G OstuzziDepartment of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry,University of Verona,Verona,Italy.
D PapolaDepartment of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry,University of Verona,Verona,Italy.
C GastaldonDepartment of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry,University of Verona,Verona,Italy.
C BarbuiDepartment of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry,University of Verona,Verona,Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-month long-acting paliperidone is a new, recently marketed, formulation of paliperidone, characterised by the longest available dosing interval among long-acting antipsychotics. The clinical profile of 3-month long-acting paliperidone was recently summarised by the European Medicines Agency (EMA) in a public assessment report, released in April 2016. In this commentary, the main strengths and limitations of the EMA assessment report were appraised and discussed, in order to highlight possible implications for clinical practice, future research and regulatory practices for drug approval.

Indexed as

Clinical Decision-MakingHealth PolicyAntipsychotic AgentsEuropeEvidence-Based PracticeHumansInjectionsPaliperidone PalmitateResearch ReportSchizophreniaAntipsychotic AgentsPaliperidone PalmitateAntipsychoticsevidence-based psychiatrypsychosisresearch design and methods

Identifiers

PMID28004623
PMCPMC6998643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.